Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02375841 |
Recruitment Status :
Recruiting
First Posted : March 3, 2015
Last Update Posted : August 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Brain Cancer Glioblastoma | Behavioral: psychometric tests, questionnaires and neurocognitive assessments |
Study Type : | Observational |
Estimated Enrollment : | 400 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers |
Actual Study Start Date : | February 2015 |
Estimated Primary Completion Date : | February 2019 |
Estimated Study Completion Date : | February 2019 |
Group/Cohort | Intervention/treatment |
---|---|
Physicians, Patients, and Caregivers
This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
|
Behavioral: psychometric tests, questionnaires and neurocognitive assessments |
- number of responses from patients, to 3 yes/no questions [ Time Frame: 2 years ]The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)
- number of responses from caregivers to 3 yes/no questions [ Time Frame: 2 years ]The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)
- number of responses from physicians to 3 yes/no questions [ Time Frame: 2 years ]The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Patient Inclusion Criteria:
- 18 years or older
- Pathologic diagnosis of WHO grade IV glioma, as per MSKCC medical record or outside medical record.
- In the judgment of the consenting professional, proficiency in English that will allow the participant to be able to complete study questionnaires and assessments. Many of the study assessments are available only in English.
- At the time of consent, orientation to self, place, month and year
Caregiver Inclusion Criteria:
- 18 years or older
- Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her informal (unpaid) care (i.e., physical or emotional assistance).
- In the judgment of the consenting professional, proficiency in English that will allow to complete study questionnaires and assessments. Many of the study assessments are available only in English.
Oncologist Inclusion Criteria:
- Treating Neuro-Oncologist in the Department of Neurology
Exclusion Criteria:
Patient Exclusion Criteria:
- A patient will be excluded if in the opinion of his/her attending neuro-oncologist or the covering neuro-oncologist, he does not have the capacity to consent to the study based on clinical evaluation
- Aphasia precluding comprehension and verbalization of consent to participate, in the estimation of the attending physician.
Caregiver Exclusion Criteria:
- There are no caregiver exclusion criteria.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02375841
Contact: Eli Diamond, MD | 212-639-7576 | ||
Contact: Allison Applebaum, PhD | 646-888-0034 |
United States, Michigan | |
Henry Ford Hospital | Recruiting |
Detroit, Michigan, United States, 48202 | |
Contact: Tobias Walbert, MD 800-436-7936 | |
Principal Investigator: Clara Hwang, MD | |
United States, New Jersey | |
Memoral Sloan Kettering Basking Ridge | Recruiting |
Basking Ridge, New Jersey, United States, 07920 | |
Contact: Eli Diamond, MD 212-610-0243 | |
Memorial Sloan Kettering Monmouth | Recruiting |
Middletown, New Jersey, United States, 07748 | |
Contact: Eli Diamond, MD 212-610-0243 | |
Memorial Sloan Kettering Bergen | Recruiting |
Montvale, New Jersey, United States, 07645 | |
Contact: Eli Diamond, MD 212-610-0243 | |
United States, New York | |
Memorial Sloan Kettering Commack | Recruiting |
Commack, New York, United States, 11725 | |
Contact: Eli Diamond, MD 212-610-0243 | |
Memorial Sloan Kettering Westchester | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Eli Diamond, MD 212-610-0243 | |
Memoral Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Eli Diamond, MD 212-610-0243 | |
Contact: Allison Applebaum, PhD 646-888-0034 | |
Principal Investigator: Eli Diamond, MD | |
United States, Vermont | |
University of Vermont Medical Center | Recruiting |
Burlington, Vermont, United States, 05401 | |
Contact: Alissa Thomas, MD 802-847-8400 |
Principal Investigator: | Eli Diamond, MD | Memorial Sloan Kettering Cancer Center |
Additional Information:
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT02375841 History of Changes |
Other Study ID Numbers: |
15-034 |
First Posted: | March 3, 2015 Key Record Dates |
Last Update Posted: | August 29, 2018 |
Last Verified: | August 2018 |
Keywords provided by Memorial Sloan Kettering Cancer Center:
Communication Physicians Patients Caregivers 15-034 |
Additional relevant MeSH terms:
Glioblastoma Brain Neoplasms Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |